Kava ： Hyperarousal and Cognitive Insomnia
A エビデンス 複数の大規模臨床試験が一貫して有意な効果を示しています。Based on 23 studies (4 meta-analyses, 1 RCT) with 2,043 total participants. Results are mixed across studies.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'sleepcited.com';
const params = 'ingredient\u003Dkava\u0026condition\u003Dhyperarousal\u002Dinsomnia';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
A
結論
Based on 23 studies (4 meta-analyses, 1 RCT) with 2,043 total participants. Results are mixed across studies.
Key Study Findings
Case Reports
n=1
6 weeks
Diagnosing Acute Kava Dermopathy: A Case Report of a Characteristic Cutaneous Eruption.
Dose: None
vs: None
Outcome: acute kava dermopathy with sebaceous gland necrosis
効果: None
None
対象集団: 41-year-old Australian woman consuming kava for anxiety and insomnia
Case Reports
n=1
Open-label
Severe kava withdrawal managed with phenobarbital.
Dose: None
vs: None
Outcome: Resolution of kava withdrawal symptoms
効果: None
None
対象集団: 45-year-old man with kava and kratom withdrawal
Other
Double-blind
The potential of AB-free kava in enabling tobacco cessation via management of abstinence-related stress and …
Dose: AB-free kava extract
vs: Placebo
Outcome: Tobacco cessation via stress/insomnia management
効果: None
None
対象集団: Adult smokers (trial protocol)
Controlled Clinical Trial
Acute oral toxicity, antinociceptive and antimicrobial activities of kava dried extracts and synthetic kavain.
Dose: None
vs: Vehicle control
Outcome: Acute oral toxicity, antinociceptive activity
効果: None
None
対象集団: Animal model
Systematic Review
The Impact of Complementary and Alternative Medicine on Insomnia: A Systematic Review.
Dose: None
vs: None
Outcome: Sleep quality improvement
効果: None
None
対象集団: Insomnia patients
Review
Calm Down With Kava: What Clinicians Need to Know.
Dose: None
vs: None
Outcome: None
効果: None
None
対象集団: Kava users
Key Statistics
23
研究数
2043
参加者数
↔
Mixed
A
グレード
Referenced Papers
The Medical journal …
2026
The American journal …
2025
1 件の引用
BMC complementary medicine …
2024
1 件の引用
Journal of clinical …
2022
27 件の引用
Cureus
2022
17 件の引用
Natural product research
2022
3 件の引用
Journal of psychosocial …
2022
2 件の引用
Combinatorial chemistry & …
2021
16 件の引用
Journal of clinical …
2020
17 件の引用
Chemical research in …
2019
6 件の引用
Natural Products from Single Plants as Sleep Aids: A Systematic Review.
Systematic Review
Journal of medicinal …
2018
19 件の引用
Sleep medicine reviews
2015
152 件の引用
Holistic nursing practice
2014
10 件の引用
Toxicokinetics of kava.
Other
Advances in pharmacological …
2011
79 件の引用
FASEB journal : …
2010
110 件の引用
Journal of psychopharmacology …
2005
176 件の引用
Medicine
2005
128 件の引用
Psychopharmacology
2005
36 件の引用
Integrative cancer therapies
2004
59 件の引用
Human psychopharmacology
2003
45 件の引用
Over-the-counter sleeping pills: a survey of use in Hong Kong and a review of their constituents.
Review
General hospital psychiatry
2002
38 件の引用
Phytotherapy research : …
2001
74 件の引用
Human psychopharmacology
2001
52 件の引用
[Hematogenous contact eczema cause by phytogenic drugs exemplified by kava root extract].
Case Report
Der Hautarzt; Zeitschrift …
1996
22 件の引用
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
一般的な使用量
- sleep:
- 120-250 mg kavalactones/day, 1-2 hrs before bed
上限量： 250 mg kavalactones/day (European guidelines); limited to 3 months continuous use
研究で検討された用量
| 用量 | 期間 | 効果 | N |
|---|---|---|---|
| None | 6 weeks | Negative | 1 |
| None | -- | Positive | 1 |
| AB-free kava extract | -- | Mixed | -- |
| None | -- | Positive | -- |
| None | -- | Mixed | -- |
| None | -- | Mixed | -- |
| None | -- | Mixed | -- |
| not specified | -- | Positive | -- |
推奨摂取タイミング： 1-2 hours before bed; avoid daily use beyond 3 months without medical supervision
Safety & Side Effects
報告されている副作用
- ⚠ Drowsiness and reduced coordination
- ⚠ Hepatotoxicity (rare but serious — consult healthcare provider)
- ⚠ Skin rash (kava dermopathy) with chronic high-dose use
- ⚠ GI discomfort
既知の相互作用
- ● Alcohol — increased hepatotoxicity risk and CNS depression
- ● Hepatotoxic medications (acetaminophen, statins) — additive liver stress
- ● Benzodiazepines and sedatives — additive CNS depression
- ● CYP450 substrates (2E1, 1A2, 2D6) — kavalactones may inhibit metabolism
- ● Levodopa and dopaminergic drugs — kava may reduce efficacy
耐容上限摂取量： 250 mg kavalactones/day (European guidelines); limited to 3 months continuous use
サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。
Frequently Asked Questions
Does Kava help with Hyperarousal and Cognitive Insomnia?
Based on 23 studies with 2,043 participants, there is strong evidence from multiple clinical trials that Kava may support Hyperarousal and Cognitive Insomnia management. Our evidence grade is A (Strong Evidence).
How much Kava should I take for Hyperarousal and Cognitive Insomnia?
Studies have used various dosages. A commonly studied range is 120-250 mg kavalactones/day, 1-2 hrs before bed. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Kava?
Reported side effects may include Drowsiness and reduced coordination, Hepatotoxicity (rare but serious — consult healthcare provider), Skin rash (kava dermopathy) with chronic high-dose use, GI discomfort. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Kava and Hyperarousal and Cognitive Insomnia?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 23 peer-reviewed studies with 2,043 total participants. The overall direction of effect is mixed.
Related Evidence
に関する他の成分： Hyperarousal and Cognitive Insomnia
Kava 他の症状・状態について
References
- [1] Ali Abid et al.. Med J Aust. 2026. Diagnosing Acute Kava Dermopathy: A Case Report of a Characteristic Cutaneous Eruption. doi:10.5694/mja2.70120 PubMed
- [2] William Bleifuss et al.. Am J Emerg Med. 2025. Severe kava withdrawal managed with phenobarbital. doi:10.1016/j.ajem.2025.06.016 PubMed
- [3] Chengguo Xing et al.. BMC Complement Med Ther. 2024. The potential of AB-free kava in enabling tobacco cessation via management of abstinence-related stress and insomnia: study protocol for a … doi:10.1186/s12906-024-04722-9 PubMed
- [4] Rita B Soares et al.. J Clin Med. 2022. An Updated Review on the Psychoactive, Toxic and Anticancer Properties of Kava. doi:10.3390/jcm11144039 PubMed
- [5] Kanika Verma et al.. Cureus. 2022. The Impact of Complementary and Alternative Medicine on Insomnia: A Systematic Review. doi:10.7759/cureus.28425 PubMed
- [6] Juliana Veloso Ferreira et al.. Nat Prod Res. 2022. Acute oral toxicity, antinociceptive and antimicrobial activities of kava dried extracts and synthetic kavain. doi:10.1080/14786419.2021.1973459 PubMed
- [7] Deana Goldin et al.. J Psychosoc Nurs Ment Health Serv. 2022. Calm Down With Kava: What Clinicians Need to Know. doi:10.3928/02793695-20220523-02 PubMed
- [8] Ruhi Ali et al.. Comb Chem High Throughput Screen. 2021. Nutraceuticals for Sleep Disorders. doi:10.2174/1386207324666210121111446 PubMed
- [9] Jennifer L Martin et al.. J Clin Sleep Med. 2020. The Veterans Administration and Department of Defense clinical practice guidelines for the diagnosis and management of sleep disorders: what does … doi:10.5664/jcsm.8486 PubMed
- [10] Pengcheng Wang et al.. Chem Res Toxicol. 2019. Enzymes and Pathways of Kavain Bioactivation and Biotransformation. doi:10.1021/acs.chemrestox.9b00098 PubMed
- [11] Jungyoon Kim et al.. J Med Food. 2018. Natural Products from Single Plants as Sleep Aids: A Systematic Review. doi:10.1089/jmf.2017.4064 PubMed
- [12] Matthew J Leach et al.. Sleep Med Rev. 2015. Herbal medicine for insomnia: A systematic review and meta-analysis. doi:10.1016/j.smrv.2014.12.003 PubMed
- [13] Stephanie Maxine Ross. Holist Nurs Pract. 2014. Psychophytomedicine: an overview of clinical efficacy and phytopharmacology for treatment of depression, anxiety and insomnia. doi:10.1097/HNP.0000000000000040 PubMed
- [14] Anthony Rowe et al.. Adv Pharmacol Sci. 2011. Toxicokinetics of kava. doi:10.1155/2011/326724 PubMed
- [15] Ping Zhou et al.. FASEB J. 2010. Flavokawain B, the hepatotoxic constituent from kava root, induces GSH-sensitive oxidative stress through modulation of IKK/NF-kappaB and MAPK signaling pathways. doi:10.1096/fj.10-163311 PubMed
- [16] David Wheatley. J Psychopharmacol. 2005. Medicinal plants for insomnia: a review of their pharmacology, efficacy and tolerability. doi:10.1177/0269881105053309 PubMed
- [17] Bradly P Jacobs et al.. Medicine (Baltimore). 2005. An internet-based randomized, placebo-controlled trial of kava and valerian for anxiety and insomnia. doi:10.1097/01.md.0000172299.72364.95 PubMed
- [18] Kazuaki Shinomiya et al.. Psychopharmacology (Berl). 2005. Effects of kava-kava extract on the sleep-wake cycle in sleep-disturbed rats. doi:10.1007/s00213-005-2196-4 PubMed
- [19] Keith I Block et al.. Integr Cancer Ther. 2004. Safety and efficacy of herbal sedatives in cancer care. doi:10.1177/1534735404265003 PubMed
- [20] Sheree Cairney et al.. Hum Psychopharmacol. 2003. Saccade and cognitive impairment associated with kava intoxication. doi:10.1002/hup.532 PubMed
- [21] Ka Fai Chung et al.. Gen Hosp Psychiatry. 2002. Over-the-counter sleeping pills: a survey of use in Hong Kong and a review of their constituents. doi:10.1016/s0163-8343(02)00210-4 PubMed
- [22] D Wheatley. Phytother Res. 2001. Kava and valerian in the treatment of stress-induced insomnia. doi:10.1002/ptr.840 PubMed
- [23] David Wheatley. Hum Psychopharmacol. 2001. Stress-induced insomnia treated with kava and valerian: singly and in combination. doi:10.1002/hup.299 PubMed
- [24] R Süss et al.. Hautarzt. 1996. [Hematogenous contact eczema cause by phytogenic drugs exemplified by kava root extract]. doi:10.1007/s001050050451 PubMed
FDAに関する免責事項: これらの記述は米国食品医薬品局（FDA）による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。